Becton, Dickinson and Company

US$211.88As of Sun 8 Nov 2026, 12:00 UTC
NYSE:BDXHealthcare
Country USA
PE (Fwd) •••
TSR 10Y CAGR 6.77%
Div yield 2.00%
ROE 5.66%
Medical Instruments & Supplies
Beta (5Y) 0.28
PE TTM 51.78
TSR TTM 54.64%
Mkt cap US$57.71B
ROIC 5.92%
SE Grade™
Value
Quality
Moat
Consensus
Reference
$238
12.13%
(69.51%)
Hold 5|11|4|4|1
1Q26
2Q26
3Q26
4Q26
Earnings per share$
2.05
2.02
2.10
2.25
6.04%
8.96%
9.45%
12.81%
Revenue$B
3.190
3.191
3.272
3.209
4.62%
1.55%
5.07%
1.63%
Peers (US$57.71B)
Cap (US$)
PE
52.14B
60.81x
33.10B
21.43x
27.85B
44.91x
47.28B
26.66x
Capital
TTM
5Y
10Y
Leveragex
1.915
(0.149)
(0.143)
EBIT/Intx
0.465
0.558
0.516
Own earn%
63.44
14.45
(4.61)
Sh yield%
45.69
25.55
23.69
Owners
Insiders/Inst%
7.42
50.45
Short interest%
1.94
SBC / revenue%
4.36
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
9
Op margin range%
22–27
$1 testx
0.1
Incr. ROIC%
−6

Becton, Dickinson and Company develops, manufactures and sells medical supplies, devices, laboratory equipment and diagnostic products worldwide to healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. Products include IV catheters, syringes and needles, medication dispensing systems, diagnostic assays, cell analyzers and surgical products.